Showing results (31-40 of 103) with videos related to
Sort By:
Pageof 11
Neurology|April 6, 2026
Industry Payments and Prescribing of Brand-Name Multiple Sclerosis Medications in MedicareAayan N Patel, Aaron S Kesselheim, Benjamin N RomeJAMA|January 23, 2014
FDA approval of cardiac implantable electronic devices via original and supplement premarket approval pathways, 1979-2012Benjamin N Rome, Daniel B Kramer, Aaron S KesselheimJAMA Health Forum|August 17, 2022
Medicare Spending on Drugs With Accelerated Approval, 2015-2019Benjamin N Rome, William B Feldman, Aaron S KesselheimHealth Affairs (Project Hope)|June 5, 2023
Inflationary Rebates For Generic Drugs Sold Through Medicaid Saved Billions During 2017-20Benjamin N Rome, Aayan N Patel, Aaron S KesselheimJournal of Cancer Policy|February 2, 2025
An empirical investigation into concerns over quality-adjusted life-years: A review of cost-effectiveness analyses in oncologyAdam J N Raymakers, Leah Z Rand, William B Feldman, et al.The Journal of Law, Medicine & Ethics : a Journal of the American Society of Law, Medicine & Ethics|July 6, 2025
Impostor Syndrome: Fraudulent Participants in Qualitative Research Can Skew ResultsLeah Z Rand, Sarah McGraw, Junyi Wang, et al.The Milbank Quarterly|August 10, 2021
Pursuing Value-Based Prices for Drugs: A Comprehensive Comparison of State Prescription Drug-Pricing BoardsLiam Bendicksen, Benjamin N Rome, Jerry Avorn, et al.Health Affairs (Project Hope)|January 20, 2017
Six-Month Market Exclusivity Extensions To Promote Research Offer Substantial Returns For Many Drug MakersAaron S Kesselheim, Benjamin N Rome, Ameet Sarpatwari, et al.Health Affairs (Project Hope)|August 5, 2024
Biosimilar Uptake In The US: Patient And Prescriber FactorsDongzhe Hong, Aaron S Kesselheim, Ameet Sarpatwari, et al.Clinical Pharmacology and Therapeutics|October 13, 2022
Patient Out-of-Pocket Costs Following the Availability of Biosimilar Versions of InfliximabKimberly Feng, Aaron S Kesselheim, Massimiliano Russo, et al.Pageof 11